Yıl: 2020 Cilt: 50 Sayı: 2 Sayfa Aralığı: 112 - 116 Metin Dili: Türkçe DOI: 10.5222/TMCD.2020.112 İndeks Tarihi: 01-11-2020

Rothia mucilaginosa Pnömonisi: Olgu sunumu

Öz:
Rothia mucilaginosa gram-pozitif, katalaz değişken, koagulaz ve oksidaz negatif; kanlıbesiyerinde hemolizsiz, gri-beyaz koloniler oluşturan fakültatif anaerop bir bakteridir.Tüm bu özellikleri ile koagulaz-negatif stafilolok kolonilerine benzemekte ve gözdenkaçabilmektedir. Orofarenks ve üst solunum yollarının mikrobiyotasında yer almaklabirlikte, son yıllarda özellikle bağışıklık sistemi baskılanmış hastalarda enfeksiyon etke-ni olarak bildirilmektedir. Rothia mucilaginosa için antimikrobiyal duyarlılık testlerihenüz standardize edilmemiş ve optimal antimikrobiyal tedavi belirlenememiş olmaklabirlikte, sıklıkla aminoglikozidlere, kotrimaksozole ve kinolonlara dirençli olduğu bildi-rilmiştir.Bu makalede de kolon kanseri nedeniyle kemoterapi alan ve kronik obstruktif akciğerhastalığı olan bir hastada Rothia mucilaginosa’nın neden olduğu bir pnömoni olgususunulmaktadır.
Anahtar Kelime:

Rothia mucilaginosa Pneumonia: Case report

Öz:
Rothia mucilaginosa is a gram-positive, catalase variable, coagulase and oxidase negative, facultative anaerobic bacterium that forms gray-white colonies without hemolysis in blood agar media. With all these features, it resembles coagulasenegative staphylolococcus colonies and can easily be overlooked. Although it is considered as a part of the microbiota of the oropharynx and upper airways, it has been reported as an infectious agent in recent years, especially in immunocompromised patients. Although antimicrobial susceptibility tests for Rothia mucilaginosa have not yet been standardized and optimal antimicrobial therapy has not been established, it has often been reported to be resistant to aminoglycosides, cotrimoxazole and quinolones. In this article, we present a case of pneumonia caused by Rothia mucilaginosa in a patient who received chemotherapy for colon cancer and also has chronic obstructive pulmonary disease
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Maraki S, Papadakis IS. Rothia muciloginosa pneumonia: a literature review. Infect Dis (Lond). 2015;47(3):125-9. https://doi.org/10.3109/00365548.2014.980843
  • 2. Collins MD, Hutson RA, Båverud V, Falsen E. Characterization of a Rothia-like organism from a mouse: Rothia nasimurium sp. nov. and reclassification of Stomatococcus mucilaginosus as Rothia mucilaginosa comb. nov. Int J Syst Evol Microbiol. 2000;50 Pt 3:1247-51. https://doi.org/10.1099/00207713-50-3-1247
  • 3. Rubin SJ, Lyons RW, Murcia AJ. Endocarditis associated with cardiac catheterization due to a gram-positive coccus designated Micrococcus mucilaginosus incertae sedis. J Clin Microbiol. 1978;7(6):546-9.
  • 4. Turhanoğlu NM, Koyuncu E, Tekay F, Yıldırım F. Rothia muciloginosa pnömonisi. Flora. 2016;21(4):186-90. https://doi.org/10.5578/flora.25245
  • 5. Sadıç B, Başaran S, Kuşkucu M, ve ark. Bir akciğer kanseri hastasında Rothia muciloginosa’nın neden olduğu nozokomiyal pnömoni. Klimik Derg. 2014;27(3):121-3. https://doi.org/10.512/kd.2014.34
  • 6. Baeza Martínez C, Zamora Molina L, García Sevila R, Gil Carbonell J, Ramos Rincon JM, Martín Serrano C. Rothia mucilaginosa pneumonia in an immunocompetent patient. Arch Bronconeumol. 2014;50(11):493-5. https://doi.org/10.1016/j.arbres.2013.12.010
  • 7. Kayman T, Akalin T, Ugur H, Bozdogan B, Duyan S. Two bacteremia cases associated with Rothia mucilaginosa. Clin Lab. 2013;59(9-10):1167-70. https://doi.org/10.7754/clin.lab.2013.130142
  • 8. Úbeda-Iglesias A, Sánchez-Porto A, Alonso-Romero L, Casas-Ciria J, Eiros JM. Severe community-acquired pneumonia caused by Rothia mucilaginosa in an immunocompetent patient. Rev Esp Quimioter. 2017;30(2):136-7.
  • 9. De Escalante Yangüela B, Gracia Gutiérreza, Gracia Tello B, Alastrué del Castaño V, Bueno Juana E, Algárate Cajo S. Bilateral bronchopneumonia due to Rothia mucilaginosa. An Sist Sanit Navar. 2017;40(3):479-83. https://doi.org/10.23938/ASSN.0090
  • 10. Chavan RS, Pannaraj PS, Luna R, et al. Significant morbidity and mortality attributable to Rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. Pediatr Hematol Oncol. 2013;30(5): 445-54. https://doi.org/10.3109/08880018.2013.783893
  • 11. Ramos JM, Mateo I, Vidal I, Rosillo EM, Merino E, Portilla J. Infection due to Rothia mucilaginosa. A respiratory pathogen?. Enferm Infecc Microbiol Clin. 2014;32(5):306-9. https://doi.org/10.1016/j.eimc.2013.12.009
  • 12. Reynolds HY, Elias JA. Pulmonary defense mechanisms against infections. In: Fishman AP, editor. Fishman ’s Pulmonary Diseases and Disorders. 3rd Ed. McGrawHill ; 1998:265-74.
  • 13. EUCAST. European Committee on Antimicrobial Susceptibility Testing (EUCAST) http://www.eucast. org/ast_of_bacteria/guidance_documents/ [Erişim tarihi: 03.01.2019]
  • 14. Sánchez-Carrillo C, Cercenado E, Cibrian F, Bouza E. Stomatococcus mucilaginosus pneumonia in a livertransplant patient. Clin Microbiol Newslett. 1995;17(7):54-5. https://doi.org/10.1016/0196-4399(95)80009-3
  • 15. Korsholm TL, Haahr V, Prag J. Eight cases of lower respiratory tract infection caused by Stomatococcus mucilaginosus. Scand J Infect Dis. 2007;39(10):913-7https://doi.org/10.1080/00365540701387064
  • 16. Cho EJ, Sung H, Park SJ, Kim MN, Lee SO. Rothia mucilaginosa diagnosed by quantitative cultures and intracellular organisms of bronchoalveolar lavage in a lymphoma patient. Ann Lab Med. 2013;33(2):145-9. https://doi.org/10.3343/alm.2013.33.2.145
  • 17. Von Eiff C, Herrmann M, Peters G. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Agents Chemother. 1995;39(1):268-70. https://doi.org/10.1128/aac.39.1.268
APA nalça erdin b, Karabiber N, Kadı H (2020). Rothia mucilaginosa Pnömonisi: Olgu sunumu. , 112 - 116. 10.5222/TMCD.2020.112
Chicago nalça erdin begüm,Karabiber Nihal,Kadı Hüseyin Rothia mucilaginosa Pnömonisi: Olgu sunumu. (2020): 112 - 116. 10.5222/TMCD.2020.112
MLA nalça erdin begüm,Karabiber Nihal,Kadı Hüseyin Rothia mucilaginosa Pnömonisi: Olgu sunumu. , 2020, ss.112 - 116. 10.5222/TMCD.2020.112
AMA nalça erdin b,Karabiber N,Kadı H Rothia mucilaginosa Pnömonisi: Olgu sunumu. . 2020; 112 - 116. 10.5222/TMCD.2020.112
Vancouver nalça erdin b,Karabiber N,Kadı H Rothia mucilaginosa Pnömonisi: Olgu sunumu. . 2020; 112 - 116. 10.5222/TMCD.2020.112
IEEE nalça erdin b,Karabiber N,Kadı H "Rothia mucilaginosa Pnömonisi: Olgu sunumu." , ss.112 - 116, 2020. 10.5222/TMCD.2020.112
ISNAD nalça erdin, begüm vd. "Rothia mucilaginosa Pnömonisi: Olgu sunumu". (2020), 112-116. https://doi.org/10.5222/TMCD.2020.112
APA nalça erdin b, Karabiber N, Kadı H (2020). Rothia mucilaginosa Pnömonisi: Olgu sunumu. Türk Mikrobiyoloji Cemiyeti Dergisi, 50(2), 112 - 116. 10.5222/TMCD.2020.112
Chicago nalça erdin begüm,Karabiber Nihal,Kadı Hüseyin Rothia mucilaginosa Pnömonisi: Olgu sunumu. Türk Mikrobiyoloji Cemiyeti Dergisi 50, no.2 (2020): 112 - 116. 10.5222/TMCD.2020.112
MLA nalça erdin begüm,Karabiber Nihal,Kadı Hüseyin Rothia mucilaginosa Pnömonisi: Olgu sunumu. Türk Mikrobiyoloji Cemiyeti Dergisi, vol.50, no.2, 2020, ss.112 - 116. 10.5222/TMCD.2020.112
AMA nalça erdin b,Karabiber N,Kadı H Rothia mucilaginosa Pnömonisi: Olgu sunumu. Türk Mikrobiyoloji Cemiyeti Dergisi. 2020; 50(2): 112 - 116. 10.5222/TMCD.2020.112
Vancouver nalça erdin b,Karabiber N,Kadı H Rothia mucilaginosa Pnömonisi: Olgu sunumu. Türk Mikrobiyoloji Cemiyeti Dergisi. 2020; 50(2): 112 - 116. 10.5222/TMCD.2020.112
IEEE nalça erdin b,Karabiber N,Kadı H "Rothia mucilaginosa Pnömonisi: Olgu sunumu." Türk Mikrobiyoloji Cemiyeti Dergisi, 50, ss.112 - 116, 2020. 10.5222/TMCD.2020.112
ISNAD nalça erdin, begüm vd. "Rothia mucilaginosa Pnömonisi: Olgu sunumu". Türk Mikrobiyoloji Cemiyeti Dergisi 50/2 (2020), 112-116. https://doi.org/10.5222/TMCD.2020.112